Integra LifeSciences Holdings (IART)

Pretax margin

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Earnings before tax but after interest (EBT)	US$ in thousands	-18,237	81,069	213,894	214,677	93,520
Revenue	US$ in thousands	1,608,880	1,486,360	1,506,670	1,533,950	1,298,690
Pretax margin		-1.13%	5.45%	14.20%	14.00%	7.20%

December 31, 2024 calculation

Pretax margin = EBT ÷ Revenue
= $-18,237K ÷ $1,608,880K
= -1.13%

Integra LifeSciences Holdings' pretax margin has shown fluctuating performance over the past five years.

In December 2020, the pretax margin stood at 7.20%, indicating that for every dollar of revenue, the company was generating a profit of 7.20 cents before taxes.

The following year, in December 2021, the pretax margin improved significantly to 14.00%, demonstrating improved efficiency in managing operating costs and higher profitability relative to revenues.

The positive trend continued into December 2022, with a slight increase in the pretax margin to 14.20%, reflecting continued strong performance in cost management and revenue generation.

However, in December 2023, there was a notable decline in the pretax margin to 5.45%, signaling a potential decrease in profitability efficiency or an increase in operating costs relative to revenues.

The most recent data point, as of December 2024, shows a negative pretax margin of -1.13%, indicating that the company incurred losses before accounting for taxes, possibly due to significant operating costs outweighing the revenue generated during that period.

Overall, while Integra LifeSciences Holdings has demonstrated periods of strong profitability, the recent decline and negative pretax margin highlight the importance of closely monitoring cost management and revenue generation strategies to sustain and improve financial performance in the future.